- Report
- May 2023
- 142 Pages
Global
From €2434EUR$2,499USD£2,081GBP
- Report
- October 2023
- 181 Pages
Global
From €4772EUR$4,900USD£4,080GBP
- Report
- July 2023
- 220 Pages
Global
€4670EUR$4,795USD£3,993GBP
- Report
- August 2022
- 120 Pages
Global
From €4626EUR$4,750USD£3,955GBP
- Report
- November 2021
- 802 Pages
Global
From €4870EUR$5,000USD£4,163GBP
The Infectious Disease Gene Therapy market is a subset of the larger Genomics market, which focuses on the study of genes and their functions. It is a rapidly growing field, with a focus on developing treatments for infectious diseases. This includes the development of gene-based therapies, such as gene editing, gene silencing, and gene replacement. These therapies are designed to target the underlying cause of the disease, rather than just treating the symptoms.
Infectious Disease Gene Therapy is a promising field, with potential to revolutionize the way we treat infectious diseases. It has the potential to reduce the burden of disease, improve patient outcomes, and reduce healthcare costs.
Companies in the Infectious Disease Gene Therapy market include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Sangamo Therapeutics. Show Less Read more